Treatment of cancer‐associated venous thromboembolism: 12‐month outcomes of the placebo versus rivaroxaban randomization of the SELECT‐D Trial (SELECT‐D: 12m) (Journal of Thrombosis and Haemostasis, 2020)

(untitled) - Marshall, A; Levine, M; Hill, C; Hale, D; Thirlwall, J; Wilkie, V; French, K; Kakkar, A; Lokare, A; Maraveyas, A; Chapman, O; Arif, A; et al.